Tag: Lenacapavir

In June 2025, the U.S. Food and Drug Administration (FDA) approved Yeztugo (lenacapavir) as the first and only twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP). The mechanism of action of Yeztugo involves targeting the viral capsid at multiple points in the HIV-1 life cycle.

In recent clinical trials, lenacapavir demonstrated a 96% lower incidence of HIV infection compared to background incidence for prevention. This incredible efficacy stems from the fact that lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor, offering a groundbreaking new approach to managing and preventing HIV.